Uncategorized
Twice-daily dose of trabodenoson may lower IOP in glaucoma patients
Twice-daily 50 µg to 500 µg ocular doses of trabodenoson were well-tolerated, according to a study, and at 500 µg, a dose-related decrease in IOP was seen in patients with primary open-angle glaucoma or ocular hypertension.The multicenter, randomized, double-masked, placebo-controlled, dose-escalation phase 2 study included 141 patients who were administered 50 µg, 100 µg or 200 µg unilateral topical twice-daily trabodenoson (Inotek Pharmaceuticals) or placebo for 14 days, or 500 µg trabodenoson or placebo for 28 days.